---
title: "midostaurin"
slug: "midostaurin"
date: "2023-05-24"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自：[[upfront treatment of acute myelogenous leukemia (AML)]]

# midostaurin

- FLT3 突變會導致 AML 病人的 → 預後 ✖ 不良
- midostaurin 成 為：全球第一個一線治療 FLT3 突變陽性 AML 的 → 標靶藥物。
- 台灣 FDA 也於 2018 年 4 月核准 midostaurin，核准的 → 適應症 為：
- 新確診 為：FLT3 突變陽性的 → AML 成年病人之標準前導 (daunorubicin 併用 cytarabine) 與鞏固性化療 （高劑量 cytarabine） 時合併使用。

[Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa1614359)

### Midostaurin Plus Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia

**Information**

- **Design**: Phase 3, randomized, double-blind, placebo-controlled, multi-center
- **Number of patients**: 717
- **Patients characteristics**: Patients with newly diagnosed acute myeloid leukemia (AML) and a FLT3 mutation, 18 to 59 years of age
- **Agent**: Midostaurin plus standard chemotherapy vs placebo plus standard chemotherapy
- **Treatment line**: Frontline therapy
- **Trial Name or NCT Number**: NCT00651261

**Comparison of two groups**

| Endpoint            | Midostaurin + Chemotherapy                                | Placebo + Chemotherapy |
| ------------------- | --------------------------------------------------------- | ---------------------- |
| Overall Survival    | Hazard ratio for death, 0.78 (one-sided P=0.009)          | -                      |
| Event-Free Survival | Hazard ratio for event or death, 0.78 (one-sided P=0.002) | -                      |

**Other findings**

- The benefit of midostaurin was consistent across all FLT3 subtypes (ITD [high], ITD [low], and TKD)
- The rate of severe adverse events was similar in the two groups
- Allogeneic transplantation was allowed in both groups

**Summary**
In this phase 3 trial, the addition of midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy significantly prolonged overall and event-free survival in patients with acute myeloid leukemia (AML) and a FLT3 mutation. The benefit of midostaurin was consistent across all FLT3 subtypes, and the rate of severe adverse events was similar in both groups.

---

- 兩組常見的 → 副作用皆 為：
  - 貧血、
  - 嗜中性白血球低下、
  - 血小板低下、
  - 淋巴球減少 ↓ 、
  - 嗜中性白血球低下合併發燒、
  - 感染、
  - 腹瀉、
  - 低血鉀等，midostaurin 加標準化療組有較多貧血及皮疹的 → 副作用 (P<0.05) 。
